Stay updated on Duvelisib in Refractory Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.

Latest updates to the Duvelisib in Refractory Lymphoma Clinical Trial page
- Check2 days agoChange DetectedThe site footer revision changed from v3.8.0 to v3.8.1; the clinical trial information remains unchanged.SummaryDifference0.0%

- Check9 days agoChange DetectedThe clinical trial record for the duvelisib study is available, with its study design, eligibility criteria, outcome measures, locations, record history, and study documents.SummaryDifference60%

- Check16 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0. The study record page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedA sitewide NIH notice about terminology changes appears above the 403 error page, and the site revision label updates from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe footer now shows site revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now shows a 403 Forbidden error page instead of the study record content. The new page presents a minimal error screen with a Home link.SummaryDifference15%

Stay in the know with updates to Duvelisib in Refractory Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.